JP2013537426A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537426A5
JP2013537426A5 JP2013524945A JP2013524945A JP2013537426A5 JP 2013537426 A5 JP2013537426 A5 JP 2013537426A5 JP 2013524945 A JP2013524945 A JP 2013524945A JP 2013524945 A JP2013524945 A JP 2013524945A JP 2013537426 A5 JP2013537426 A5 JP 2013537426A5
Authority
JP
Japan
Prior art keywords
adenovirus
cancer
item
orf3
impaired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013524945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537426A (ja
JP5905460B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/048005 external-priority patent/WO2012024350A2/en
Publication of JP2013537426A publication Critical patent/JP2013537426A/ja
Publication of JP2013537426A5 publication Critical patent/JP2013537426A5/ja
Application granted granted Critical
Publication of JP5905460B2 publication Critical patent/JP5905460B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013524945A 2010-08-16 2011-08-16 抗がんアデノウイルス Active JP5905460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37421510P 2010-08-16 2010-08-16
US61/374,215 2010-08-16
PCT/US2011/048005 WO2012024350A2 (en) 2010-08-16 2011-08-16 Anti-cancer adenoviruses

Publications (3)

Publication Number Publication Date
JP2013537426A JP2013537426A (ja) 2013-10-03
JP2013537426A5 true JP2013537426A5 (enExample) 2014-09-18
JP5905460B2 JP5905460B2 (ja) 2016-04-20

Family

ID=45605646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524945A Active JP5905460B2 (ja) 2010-08-16 2011-08-16 抗がんアデノウイルス

Country Status (10)

Country Link
US (1) US9187733B2 (enExample)
EP (1) EP2606137B1 (enExample)
JP (1) JP5905460B2 (enExample)
KR (1) KR101667094B1 (enExample)
CN (1) CN103180448B (enExample)
AU (1) AU2011292119B2 (enExample)
BR (1) BR112013003579A2 (enExample)
CA (1) CA2807778C (enExample)
SG (1) SG187785A1 (enExample)
WO (1) WO2012024350A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013003579A2 (pt) * 2010-08-16 2016-06-07 Salk Inst For Biological Studi adenovírus, células, e, métodos para tratar câncer
CA2867129C (en) * 2012-03-13 2023-11-21 Salk Institute For Biological Studies Selective cell targeting using adenovirus and chemical dimers
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
ES2837400T3 (es) 2015-10-05 2021-06-30 Salk Inst For Biological Studi Adenovirus sintético con tropismo para los tejidos dañados para su uso en la promoción de la reparación de heridas y regeneración tisular
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
MX2021014525A (es) * 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA137094A (en) 1911-08-31 1911-11-28 Sheppe, Alice L. Cloth measuring and price calculating machine
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
DK1199368T3 (da) * 1998-07-07 2004-04-13 Transgene Sa Anvendelse af adenovirus-E4-læserammer til forbedring af ekspression af et gen af interesse
EP1083229A1 (en) * 1999-09-10 2001-03-14 Introgene B.V. Modified adenoviral vectors for use in gene therapy
EP1284294A4 (en) * 2000-05-26 2004-10-13 Sumitomo Pharma RECOMBINANT ADENOVIRUS WITH REDUCED SIDE EFFECTS (12/05/01)
US20020106382A1 (en) * 2000-07-14 2002-08-08 Young Charles S.H. Modified adenovirus and uses thereof
US20030220284A1 (en) 2002-02-22 2003-11-27 Patricia Yotnda Delivery of adenoviral DNA in a liposomal formulation for treatment of disease
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
US20060099709A1 (en) 2002-10-01 2006-05-11 Chuan-Yuan Li Targeted tumor therapy by use of recombinant adenovirus vectors that selectively replicate in hypoxic regions of tumors
WO2005048950A2 (en) 2003-11-17 2005-06-02 Biomune, Inc. Tumor and infectious disease therapeutic compositions
EP2352516A2 (en) * 2008-09-26 2011-08-10 Auburn University Immunization of avians by mucosal administration of non-replicating vectored vaccines
BR112013003579A2 (pt) * 2010-08-16 2016-06-07 Salk Inst For Biological Studi adenovírus, células, e, métodos para tratar câncer

Similar Documents

Publication Publication Date Title
JP2013537426A5 (enExample)
Barkauskas et al. Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
WO2012142529A3 (en) Clonal strains of attenuated vaccinia viruses and methods of use thereof
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
FR2981643B1 (fr) Procede de preparation d'un materiau composite silicium/carbone, materiau ainsi prepare, et electrode notamment electrode negative, comprenant ce materiau.
WO2015061294A8 (en) Use of sting agonists to treat chronic hepatitis b virus infection
JP2013530155A5 (enExample)
NZ748120A (en) Tri-segmented pichinde viruses as vaccine vectors
BR112014015016A8 (pt) Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
IN2015DN00376A (enExample)
BR112015008930A2 (pt) vacinas baseadas em partícula recombinante contra a infecção por citomegalovírus humano
IL187321A (en) Molecules that have a specific link to a surrogate cell that encode monoclonal antibodies capable of neutralizing viruses, medicinal preparations containing them, and their uses in drug preparation
JP2011157399A5 (enExample)
BR112018074869A2 (pt) anticorpos antagonistas que ligam t ao tgfb1, tgfb2 e ao tgfb3 humanos e seu uso para o tratamento de fibrose pulmonar
PH12014500865A1 (en) Compounds and methods for enhancing innate immune responses
NZ628385A (en) Batches of recombinant adenovirus with altered terminal ends
JP2018512597A5 (enExample)
MD4481B1 (ro) Herpesvirus recombinant Koi (KHV) şi vaccin pentru profilaxia bolii cauzate de KHV
JP2013544892A5 (enExample)
Hu et al. Oncolytic viruses for the treatment of bladder cancer: advances, challenges, and prospects
JP2014515258A5 (enExample)